OMB No. 0925-0613 **Expiration Date: 03/31/2016**



Collection of this information is authorized under 21 CFR 312.53. Collection of this information serves two purposes. The first is to identify qualified investigators and associates to participate in clinical investigations at the National Cancer Institute. This information may be disclosed to researchers for research purposes, sponsors of clinical trials, the applicable Institutional Review Board, National Cancer Institute, Food and Drug Administration's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, and the Department of Health and Human Services. The second purpose is to ensure that investigational agents are under the control and accounted for by a competent authority. Submission of this information is voluntary, however, in order for us to qualify you

to conduct a study in accordance with the relevant, current protocol(s), you must complete all fields. **Public reporting burden** for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. **An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number**. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0613). Do not return the completed form to this address.

Sl	JPPLEN	/ENTAL IN\	/ESTIGATO	OR DATA FORM Date (MM/I	DD/YYYY)://	/
Sections 1 – 12: REQUIRED INFORI	MATION	(Collected for	all investiga	tors participating in CTEP-sponsored c	linical trials.)	
Investigator Name (Last, First, Middle, Suffix):				2. Degree(s):	3. CTEP Investigator ID:	
4. Date of Birth (MM/YYYY):	5. Provider No. (NPI):			Are you currently licensed to practice medicine	☐ YES ☐ NO	
7. Primary Specialty Practice(s): Check all that	apply.	Board	Board		Board	Board
		Eligible:	Certified:		Eligible:	Certified:
Anatomic and/or Clinical Pathology				Obstetrics and Gynecology		
Clinical Genetics				Orthopedic Surgery		
Colon and Rectal Surgery				Otolaryngology		
Dermatology				Pediatric Hematology-Oncology		
Diagnostic Radiology				Pediatrics		
Family Practice				Psychiatry		
Gastroenterology				Public Health and General Preventative Medicine		
Gynecological Oncology				Radiation Oncology		
Hematology				Surgery		
Internal Medicine				Surgical Oncology		
Medical Oncology				Thoracic Surgery		
Neurological Surgery	-			Urology		
Neurology				Other		
8. Have you received training in:		Completion of	f this training	is mandatory for all CTEP-registered in	nvestigators.	
"Protection of Human Research Participants"?		☐ YES	DATE CO	MPLETED (MM/YYYY): /		
In sections 9 – 12, use this side to either ente information.	er new infol	rmation or view co	urrent	In sections 9 – 12, use this side to make chang	es to current informat	ion only.
9. Office Address: The office address and conta	act informati	ion will be used for	r receipt of all offi	cial correspondence.		
Institution:				Institution:		
Internal Office:				Internal Office:		
Street Address:				Street Address:		
Street Address:				Street Address:		
City:				City:		
State/Province:				State/Province:		
Zip/Postal Code:				Zip/Postal Code:		
Country:				Country:		
Office Phone No.:				Office Phone No.:		
Office FAX No.:				Office FAX No.:		
Office E-mail:				Office E-mail:		
	er and email	address, suitable	for display on a p	ublicly accessible website (e.g., www.cancer.gov), w	hich can be used by a p	atient to
contact the investigator's research staff to inquire	e about clini	ical trials approved	I by their IRB and	open for enrollment at their institution.		
Research Contact Phone No.				Research Contact Phone No.		
Research Contact E-mail address				Research Contact E-mail address		



11. Primary Shipping Address: The primary shipping address will be used for receipt of all CT	FEP-supplied investigational agents.				
Institution:	Institution:				
Internal Office:	Internal Office:				
Street Address:	Street Address:				
Street Address:	Street Address:				
City:	City:				
State/Province:	State/Province:				
Zip/Postal Code:	Zip/Postal Code:				
Country:	Country:				
Shipping Designee: Provide name of shipping designee (preferably a pharmacist) appro	oved to order and receive CTEP-supplied investigational agents.				
Shipping Designee Name:	Shipping Designee Name:				
Shipping Designee Phone No.:	Shipping Designee Phone No.:				
Shipping Designee FAX No.:	Shipping Designee FAX No.:				
Shipping Designee E-mail:	Shipping Designee E-mail:				
CTEP USE ONLY: ☐ PSD ☐ SD ☐ IA					
12. Ordering Designee(s): Provide name(s) of ordering designee(s) approved to order CTEP					
CTEP-supplied agent must be signed by either the investigator, the authorized shipping	g designee (from item #11), or an ordering designee (from item #12). An ordering				
designee must use the primary shipping address (from item #11).	A Orderina Desirana Nama				
A. Ordering Designee Name:	A. Ordering Designee Name:				
Ordering Designee Phone No.:	Ordering Designee Phone No.:				
Ordering Designee Fax No.:	Ordering Designee Fax No.:				
Ordering Designee E-mail:	Ordering Designee E-mail:				
B. Ordering Designee Name:	B. Ordering Designee Name:				
Ordering Designee Phone No.:	Ordering Designee Phone No.:				
Ordering Designee Fax No.:	Ordering Designee Fax No.:				
Ordering Designee E-mail:	Ordering Designee E-mail:				
C. Ordering Designee Name:	C. Ordering Designee Name:				
Ordering Designee Phone No.:	Ordering Designee Phone No.:				
Ordering Designee Fax No.:	Ordering Designee Fax No.:				
Ordering Designee E-mail:	Ordering Designee E-mail:				
Please be sure you have also included: 1. Completed FDA Form 1572 with original	signature.				
Current Curriculum Vitae (CV). Consolidated File OTERad Blade over Force	will add a lateral server				
3. Completed FinaCTEPal Disclosure Form	with original signature.				
I certify that the information on this "Supplemental Investigator Data Form" is true and correct to the best of my knowledge.					
turn attraction	Dete				
Investigator:(Signature)	Date:				
(Signature)					



Section	INSTRUCTIONS FOR COMPLETING THE "SUPPLEMENTAL INVESTIGATOR DATA FORM"
1.	Investigator Name: Provide legal last name, first name, middle initial or name, and suffix (if applicable).
2.	Degree(s): Provide degree(s) (e.g., M.D., D.O., foreign M.D. equivalent).
3.	CTEP Investigator ID: Provide the unique CTEP investigator number assigned to the investigator by the Pharmaceutical Management Branch (PMB), CTEP, DCTD, CTEP at the time of initial registration. (If an investigator has never registered to participate in CTEP-sponsored clinical trials, leave field blank. An CTEP Investigator ID will be assigned by the PMB as part of the registration process.)
4.	Date of Birth: Indicate the investigator's date of birth (in MM/YYYY format).
5.	Provider No. (NPI): Indicate the investigator's National Provider Identifier (NPI).
6.	Medical License: Indicate if the investigator is currently licensed to practice medicine.
7.	Primary Specialty Practice(s): Indicate the investigator's primary specialty practice(s). Board Eligibile: Indicate if the investigator is eligible for Board Certification in the primary specialty practice(s) selected. Board Certified: Indicate if the investigator is Board Certified in the primary specialty practice(s) selected.
8.	Investigator Training: Indicate if the investigator has completed the NIH-mandated training in the protection of human research participants, including date completed (in MM/YYYY format). If needed, additional information and online training are available at http://phrp.nihtraining.com . The online training takes approximately one hour to complete. Completion of protection of human research participants training is mandatory for ALL CTEP-registered investigators.
9.	Office Address: The office address will be used for receipt of all official correspondence (e.g., annual registration and protocol documents). Include institution, internal office, street, city, state/province, zip/postal code, and country. Office Phone No.: Provide daytime phone number at which the investigator can be reached during normal business hours, including area code. Investigators from outside the United States should also include the country code. Office Fax No.: Provide Fax number at which the investigator usually receives faxes, including area code. Investigators from outside the United States should also include the country code. Office E-mail: Provide E-mail address at which the investigator usually receives e-mail. This address will be used to send information regarding protocols, investigator brochures, stock recovery letters, investigator expiry information, and general information for the investigator.
10.	Research Contact: Provide a phone number and email address, suitable for display on a publicly accessible website (e.g., www.cancer.gov), which can be used by a patient to contact the investigator's research staff to inquire about clinical trials approved by their IRB and open for enrollment at their institution.
11.	Primary Shipping Address: The primary shipping address will be used for receipt of all CTEP-supplied investigational agents. Include institution, internal office, street, city, state/province, zip/postal code, and country. Shipping Designee: Provide name of shipping designee (preferably a pharmacist) approved to order and receive CTEP-supplied agents. Note that a "Clinical Drug Request (CDR) Form" for a CTEP-supplied agent must be signed by either the investigator, the authorized shipping designee (from item #11), or an ordering designee (from item #12). Shipping Designee Phone No.: Provide daytime phone number at which the shipping designee can be reached during normal business hours, including area code. Shipping designees from outside the United States should also include the country code. Shipping Designee Fax No.: Provide Fax number at which the shipping designee usually receives faxes, including area code. Shipping designees from outside the United States should also include the country code. Shipping Designee E-mail: Provide E-mail address at which the shipping designee usually receives e-mail. This address will be used to send information regarding drug shipments, protocols, stock recovery letters, and general information for shipping designees.
12.	Ordering Designee(s): Provide name(s) of ordering designee(s) approved to order CTEP-supplied agents. <i>Note that a "Clinical Drug Request (CDR) Form" for a CTEP-supplied agent must be signed by either the investigator, the authorized shipping designee (from item #11), or an ordering designee (from item #12). An ordering designee must use the primary shipping address (from item #11).</i> Ordering Designee Phone No.: Provide daytime phone number at which the ordering designee can be reached during normal business hours, including area code. Ordering designees from outside the United States should also include the country code. Ordering Designee Fax No.: Provide Fax number at which the ordering designee usually receives faxes, including area code. Ordering designees from outside the United States should also include the country code. Ordering Designee E-mail: Provide E-mail address at which the ordering designee usually receives e-mail. This address will be used to send information regarding drug shipments, protocols and general information for ordering designees.